Quality of life in patients with advanced basal cell carcinoma treated with sonidegib (LDE225) - 09/05/15
Michael Migden, MD, University of Texas MD Anderson Cancer Center, Houston, TX, United States; John Lear, MD, Manchester Academic Health Science Center, University of Manchester, Manchester, United Kingdom; Alexander Guminski, MBBS, PhD, Royal North Shore Hospital, St Leonards, Australia; Tingting Yi, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States; Keiko Higuchi, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States; Ralf Gutzmer, MD, Medizinische Hochschule Hannover, Hannover, Germany; Reinhard Dummer, MD, Universitätsspital Zürich—Skin Cancer Center University Hospital, Zürich, Switzerland
Le texte complet de cet article est disponible en PDF. Medical editorial assistance was provided by Articulate Science, LLC. Financial support for editorial assistance was provided by Novartis Pharmaceuticals Corporation. This study was funded by Novartis Pharmaceuticals Corporation. |
Vol 72 - N° 5S1
P. AB191 - mai 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?